Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;170(1):108-118.
doi: 10.1002/ijgo.16157. Epub 2025 Jan 25.

Meta-analysis of the ability of mutational profiles on the cancer genome atlas to predict prognosis in endometrial carcinoma

Yi-Xiang Li  1   2 , Yu Fan  1   2 , Si-Yu Cao  1   2 , Yu-Fei Zhang  1   2 , Jin-Ke Li  1
Affiliations
Review

Meta-analysis of the ability of mutational profiles on the cancer genome atlas to predict prognosis in endometrial carcinoma

Yi-Xiang Li et al. Int J Gynaecol Obstet. 2025 Jul.

Abstract

Background: In 2013, The Cancer Genome Atlas Research Network suggested that endometrial carcinoma patients may be reclassified into four molecular prognostic groups.

Objective: To compare survival of endometrial carcinoma patients with different mutational profiles.

Search strategy: Studies reporting survival of endometrial carcinoma patients were identified through systematic searches of four databases.

Selection criteria: We included relevant studies based on the literature type, data integrity and the methodological quality.

Data collection and analysis: The pooled survival data were compared among patients with different mutational profiles. Heterogeneity in the pooled data was assessed using the I2 statistic.

Main results: Data were meta-analyzed from nine studies involving 4755 patients, who were classified into the following mutational profiles: p53abn, 745 patients (15.6%); MMRd, 1454 patients (30.6%); POLEmut, 351 patients (7.4%); and p53wt, 2205 patients (46.4%). Compared to the p53wt group, the p53abn group showed significantly worse overall survival (OS) (HR 2.31, 95% CI: 1.67-3.19), progression-free survival (PFS) (HR 2.86, 95% CI: 1.45-5.64) and disease-specific survival (HR 2.60, 95% CI: 1.41-4.79); and the MMRd group showed significantly worse OS (HR 1.30, 95% CI: 1.11-1.53) and PFS (HR 1.27, 95% CI: 1.01-1.59). The POLEmut group, in contrast, showed similar survival as the p53wt group.

Conclusions: The four mutational profiles for patients with endometrial carcinoma in the Cancer Genome Atlas for Endometrial Cancer are associated with worse to better survival in the trend: p53abn < MMRd < POLEmut ≈ p53wt. Mutational profiling may be useful for stratifying endometrial carcinoma patients by survival risk, which in turn may improve their management.

Keywords: endometrial neoplasms; molecular classification; prognostic group; subgroup; survival outcome.

PubMed Disclaimer

References

REFERENCES

    1. Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet (London, England). 2022;399(10333):1412‐1428.
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7‐33.
    1. Abdulfatah E, Wakeling E, Sakr S, et al. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: towards early personalized patient management. Gynecol Oncol. 2019;154(3):467‐474.
    1. de Boer SM, Wortman BG, Bosse T, et al. Clinical consequences of upfront pathology review in the randomised PORTEC‐3 trial for high‐risk endometrial cancer. Ann Oncol. 2018;29(2):424‐430.
    1. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high‐grade endometrial carcinoma. Am J Surg Pathol. 2013;37(6):874‐881.

Substances

LinkOut - more resources